# A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

> **NCT05013905** · PHASE2 · COMPLETED · sponsor: **Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 55 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **BIOLOGICAL:** Tulisokibart
- **DIAGNOSTIC_TEST:** Companion Diagnostic (CDx)

## Key facts

- **NCT ID:** NCT05013905
- **Lead sponsor:** Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2022-09-23
- **Final completion:** 2025-05-27
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013905, "A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05013905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*